Xtant Medical Holdings, Inc. insider trading

Every open-market purchase and sale by Xtant Medical Holdings, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Xtant Medical Holdings, Inc.’s insiders pay?

From April 21, 2011 to April 14, 2025, 16 insiders reported 36 open-market purchases and 29 sales not made under a pre-set plan in Xtant Medical Holdings, Inc. Twelve months after each purchase was reported, the shares were −50.1% against the S&P 500 on average (median −50.9%), over 3 purchases with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 26, 2018 into $6,684 by November 2, 2026, −4.5% a year. It held shares 12% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $12,758 (+2.9% a year), and held throughout $31,084 (+14.0%).

Copying Xtant Medical Holdings, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Xtant Medical Holdings, Inc.'s insiders from February 26, 2018, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 12% of the time.

Xtant Medical Holdings, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Cook Guy S	CEO	12	—	—	23	—	May 9, 2014
Goldberger Daniel S	Chief Executive Officer	5	—	—	0	—	May 10, 2016
Swanson Kent L	Director	5	—	—	0	—	November 20, 2015
Holmes Darrel Lee	COO	0	—	—	4	—	July 21, 2014
Wickwire Jon M.	Director	4	—	—	0	—	September 9, 2015
Lopach Michael A	Director	2	—	—	0	—	September 9, 2015
Brandt Kevin D	Chief Commercial Officer	1	—	—	0	—	November 17, 2023
Deedrick John Arthur	Director	1	—	—	0	—	September 9, 2015
Eggenberg Michael	Director	1	−50.9% (1)	0%	0	—	February 26, 2018
Gandolfo John P	CFO	1	—	—	0	—	May 4, 2011
Godfrey Mitchell T	Director	0	—	—	1	—	August 16, 2011
Juda Gregory Alexander	Chief Scientific Officer	1	—	—	0	—	May 20, 2014
Orbimed Advisors LLC	Director	1	−48.7% (1)	0%	0	—	February 23, 2018
Orbimed Rof II LLC	10% owner	0	—	—	1	—	April 14, 2025
Rizzo Matthew	Director	1	−50.9% (1)	0%	0	—	February 26, 2018
Vizirgianakis Stavros G.	Director	1	—	—	0	—	October 11, 2022

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Xtant Medical Holdings, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Xtant Medical Holdings, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −36.9% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
February 28, 2018	3 buying	−16.8%	−36.9%	−50.1%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Xtant Medical Holdings, Inc. · Funds · Politicians